[
  "[Tab] Consolidated Statement of Income for Merck & Co., Inc. and Subsidiaries\n\n[Time]: December 31, 2023 [SEP]\n[row 0]: Sales | $60,115 [SEP]\n[row 1]: Costs, Expenses and Other | [SEP]\n[row 2]: Cost of sales | $16,126 [SEP]\n[row 3]: Selling, general and administrative | $10,504 [SEP]\n[row 4]: Research and development | $30,531 [SEP]\n[row 5]: Restructuring costs | $599 [SEP]\n[row 6]: Other (income) expense, net | $466 [SEP]\n[row 7]:   | $58,226 [SEP]\n[row 7]: Income from Continuing Operations Before Taxes | $1,889 [SEP]\n[row 8]: Taxes on Income from Continuing Operations | $1,512 [SEP]\n[row 9]: Net Income from Continuing Operations | $377 [SEP]\n[row 10]: Less: Net Income Attributable to Noncontrolling Interests | $12 [SEP]\n[row 11]: Net Income from Continuing Operations Attributable to Merck & Co., Inc. | $365 [SEP]\n[row 12]: Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | — [SEP]\n[row 13]: Net Income Attributable to Merck & Co., Inc. | $365 [SEP]\n[row 14]: Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders [SEP]\n[row 15]: Income from Continuing Operations | $0.14 [SEP]\n[row 16]: Income from Discontinued Operations | — [SEP]\n[row 17]: Net Income | $0.14 [SEP]\n[row 18]: Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders [SEP]\n[row 19]: Income from Continuing Operations | $0.14 [SEP]\n[row 20]: Income from Discontinued Operations | — [SEP]\n[row 21]: Net Income | $0.14 [SEP]\n\n[Time]: December 31, 2022 [SEP]\n[row 0]: Sales | $59,283 [SEP]\n[row 1]: Costs, Expenses and Other | [SEP]\n[row 2]: Cost of sales | $17,411 [SEP]\n[row 3]: Selling, general and administrative | $10,042 [SEP]\n[row 4]: Research and development | $13,548 [SEP]\n[row 5]: Restructuring costs | $337 [SEP]\n[row 6]: Other (income) expense, net | $1,501 [SEP]\n[row 7]:   | $42,839 [SEP]\n[row 7]: Income from Continuing Operations Before Taxes | $16,444 [SEP]\n[row 8]: Taxes on Income from Continuing Operations | $1,918 [SEP]\n[row 9]: Net Income from Continuing Operations | $14,526 [SEP]\n[row 10]: Less: Net Income Attributable to Noncontrolling Interests | $7 [SEP]\n[row 11]: Net Income from Continuing Operations Attributable to Merck & Co., Inc. | $14,519 [SEP]\n[row 12]: Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | — [SEP]\n[row 13]: Net Income Attributable to Merck & Co., Inc. | $14,519 [SEP]\n[row 14]: Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders [SEP]\n[row 15]: Income from Continuing Operations | $5.73 [SEP]\n[row 16]: Income from Discontinued Operations | — [SEP]\n[row 17]: Net Income | $5.71 [SEP]\n[row 18]: Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders [SEP]\n[row 19]: Income from Continuing Operations | $5.71 [SEP]\n[row 20]: Income from Discontinued Operations | — [SEP]\n[row 21]: Net Income | $5.71 [SEP]\n\n[Time]: December 31, 2021 [SEP]\n[row 0]: Sales | $48,704 [SEP]\n[row 1]: Costs, Expenses and Other | [SEP]\n[row 2]: Cost of sales | $13,626 [SEP]\n[row 3]: Selling, general and administrative | $9,634 [SEP]\n[row 4]: Research and development | $12,245 [SEP]\n[row 5]: Restructuring costs | $661 [SEP]\n[row 6]: Other (income) expense, net | ($1,341) [SEP]\n[row 7]:   | $34,825 [SEP]\n[row 7]: Income from Continuing Operations Before Taxes | $13,879 [SEP]\n[row 8]: Taxes on Income from Continuing Operations | $1,521 [SEP]\n[row 9]: Net Income from Continuing Operations | $12,358 [SEP]\n[row 10]: Less: Net Income Attributable to Noncontrolling Interests | $13 [SEP]\n[row 11]: Net Income from Continuing Operations Attributable to Merck & Co., Inc. | $13,049 [SEP]\n[row 12]: Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | — [SEP]\n[row 13]: Net Income Attributable to Merck & Co., Inc. | $13,049 [SEP]\n[row 14]: Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders [SEP]\n[row 15]: Income from Continuing Operations | $4.88 [SEP]\n[row 16]: Income from Discontinued Operations | $0.28 [SEP]\n[row 17]: Net Income | $5.16 [SEP]\n[row 18]: Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders [SEP]\n[row 19]: Income from Continuing Operations | $4.86 [SEP]\n[row 20]: Income from Discontinued Operations | $0.28 [SEP]\n[row 21]: Net Income | $5.14 [SEP]"
]